Act I · Physical & Clinical Story
Navigating Sixteen Generations of Branching Tubes
Translating genetic formulations into clinical reality requires conquering a complex maze of sixteen bifurcating aerodynamic chambers. In a landmark clinical evaluation published in the Journal of Cystic Fibrosis in 2023, Steven Rowe and his investigative colleagues reported interim trial results for an inhaled messenger ribonucleic acid therapy administered repeatedly to patients with cystic fibrosis. Aerosol medicine must navigate strict aerodynamic laws governing how microscopic droplets travel through the human bronchial tree. If liquid droplets are generated too large, inertial forces slam them directly into the back of the throat during inspiration. Conversely, if droplets are engineered too tiny, they float straight past diseased conducting airways and settle deep inside peripheral gas-exchange sacs. The clinical trial established that repeat-dose nebulization was physically feasible and well tolerated, while demonstrating that droplet size, inspiratory speed, and immune recognition define the true boundary between therapeutic success and clearance.
To picture how inhaled droplets travel, imagine throwing small rubber balls through a dense forest of branching trees. If you throw a heavy ball with great force, it strikes the first large tree trunk immediately. If you toss a weightless feather into the wind, it drifts past every branch without landing anywhere near the middle trunks. Medical aerosols face this identical physical challenge inside the human lungs. This creates a tight aerodynamic filter. The throat forms a sharp corner where fast-moving large droplets crash and stick before entering the windpipe. The target cells line the intermediate branches where airways narrow and air velocity slows down. Droplets must measure just the right size to negotiate that initial turn yet settle onto bronchial surfaces. Carefully coordinating droplet diameter and patient breathing speed ensures therapeutic genetic cargo reaches diseased airways effectively.
Everyday Analogy: Consider navigating an express train through a rapidly branching railway network where each junction divides tracks into two narrower rails. At the entrance of the rail yard, the main track makes a sharp ninety-degree turn around a rocky hillside. If a train approaches that initial curve at high velocity, heavy rail cars derail and crash directly into the cliff wall. However, if the train consists of featherweight balsa wood gliders moving in a gentle breeze, they float straight past all passenger stations into remote peripheral swamps. To deliver passengers successfully to intermediate suburban stations, cars must carry moderate momentum and travel at controlled speeds that allow timely stopping. This railway comparison breaks down because rail cars follow fixed steel tracks under manual braking, whereas nebulized aerosol droplets navigate stochastic gas streamlines governed by Stokes drag, thermal diffusion, and gravitational settling inside expanding biological lumens.
How the Two Sliders Work in Plain Words: Before examining the aerodynamic formulas governing aerosol motion, the interactive controls below let you adjust inhaler and patient breathing variables. The first slider sets the Mass Median Aerodynamic Diameter (median droplet size), defining the median physical size of aerosol droplets produced by the nebulizer device. The second slider controls the Inspiratory Flow Rate (inhalation speed), representing how rapidly the patient inhales during each aerosol breath. Observe how increasing breathing speed or droplet diameter drives up Oropharyngeal Impaction Loss, showing how much medication slams wastefully into the back of the throat. Simultaneously, track the primary readout for Conducting Airway Deposition, which quantifies the percentage of the inhaled dose that successfully settles within target bronchial branches. Notice how droplets that are too small escape past target airways into the Alveolar and Exhaled Fraction. Finally, the Repeat-Dose Neutralizing Ab Penalty readout highlights a major clinical advantage of non-viral lipid formulations over classical viral capsids.
Cystic fibrosis lung disease is fundamentally a disease of the conducting airways—especially the small bronchi and bronchioles from Generation 2 to Generation 14, which lack cartilage rings and easily plug with dehydrated mucus. Delivering a genetic medicine to those exact generations requires matching the aerodynamic diameter d_a of the nebulized droplets and the patient's inspiratory flow rate Q_insp to the fluid mechanics of the Weibel tree.
The clinical stakes of aerosolized genetic delivery revolve around depositing therapeutic payloads onto diseased bronchial conducting airways while preventing throat impaction and systemic toxicity. Rowe and colleagues documented the first randomized, double-blind evaluation of repeated inhaled messenger ribonucleic acid in individuals with cystic fibrosis. Their findings confirmed that non-viral lipid carrier nanoparticles can be nebulized repeatedly without triggering neutralizing antibody responses that historically halted adenoviral gene therapy trials. However, the trial revealed that clinical efficacy requires reconciling aerodynamic deposition physics with intracellular escape thresholds across complex airway geometries. Droplets must deposit specifically across Weibel generations two through fourteen, where mucus plugging and submucosal glands predominate in cystic fibrosis lung disease. Simultaneously, transient febrile reactions and mild pulmonary inflammation observed at higher doses underscore the narrow window between therapeutic channel expression and pattern-recognition receptor activation. Optimizing droplet aerodynamics and mitigating lipid-induced reactogenicity represents the critical path for next-generation clinical candidates like VX-522 and ARCT-032. Reliable delivery protocols bring genetic medicines to every airway branch.
“Synthesizes aerosol physics (Stokes impaction vs gravitational sedimentation across Weibel generations G_0–G₁₆) with vector immunology (non-viral LNP repeat dosing vs F/HN-pseudotyped lentiviral integration).”
— Cross-Pillar Research Thread · Grounded in Rowe et al. (2023), Journal of Cystic Fibrosis 22(4):656-664 — Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled Phase I/II clinical evaluation (PMID 37121795).
Key Parameters, Readouts & Primary Anchor
| Quantity / Anchor | Pinned Baseline | Physical / Clinical Role |
|---|---|---|
| Mass Median Aerodynamic Diameter (median droplet size) | 3.2 μm |
Primary perturbation axis (1.0 to 7.5 μm) |
| Inspiratory Flow Rate (inhalation speed) | 18.0 L/min |
Coupled co-perturbation axis (10.0 to 45.0 L/min) |
| Conducting Airway Deposition (G_2–G₁₄) & Oropharyngeal Impaction Loss (G_0) | 54.6% of Inhaled Dose · 14.8% (Low-Velocity Breath) |
Baseline biophysical operating point |
| Primary Literature Anchor | DOI 10.1016/j.jcf.2023.04.008 | Rowe et al. (2023), Journal of Cystic Fibrosis 22(4):656-664 — Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled Phase I/II clinical evaluation (PMID 37121795). · Kernel src/scripts/delivery-weibel-deposition.js |
Act II · From Intuition to Governing Law
Stokes Impaction St, Gravitational Sedimentation, and Vector
Three physical deposition mechanisms operate in series along the Weibel tree. In the upper airways (G_0–G_4), high air velocities U_G drive inertial impaction at bifurcations, governed by the Stokes number St = ρ_0 d_a² U_G / (18 μ_air D_G). In the mid-to-distal conducting airways (G_5–G₁₄), air velocity slows to millimeters per second and residence time τ_G = L_G / U_G lengthens, allowing gravitational sedimentation at terminal settling velocity v_s = ρ_0 g d_a² / (18 μ_air) to deposit 2–4 μm droplets directly onto the bronchiolar wall. Once deposited, non-viral LNP-mRNAs and ASOs can be redosed repeatedly because they carry no viral capsid proteins to elicit neutralizing antibodies—whereas viral vectors must either integrate into basal progenitor cells on the first dose (F/HN-pseudotyped lentivirus) or evade mucosal IgA/IgG.
The fluid mechanics of aerosol deposition across the human respiratory tract is governed by the aerodynamic equations of inertial impaction, gravitational sedimentation, and Brownian diffusion across the twenty-three dichotomous branching generations of the Weibel lung model. In the upper airway and throat (generation zero), high linear air velocity U_0 generates intense inertial forces at the ninety-degree oropharyngeal bend. Droplet trajectory divergence from air streamlines is quantified by the dimensionless Stokes number, St = ρ_0 d_a² U_G / (18 μ_air D_G), where ρ_0 is unit particle density, d_a is the mass median aerodynamic diameter, μ_air is air dynamic viscosity, and D_G is the local airway lumen diameter. When the Stokes number exceeds critical thresholds, droplet momentum overcomes aerodynamic drag, causing irreversible impaction on mucosal surfaces.
As air advances through successive bronchial bifurcations from generation two to generation fourteen, the total cross-sectional area expands exponentially as two raised to the generation number, causing linear air velocity U_G to decelerate from meters to centimeters per second. Within this conducting zone, inertial impaction diminishes and gravitational sedimentation becomes the primary deposition mechanism, governed by the settling velocity v_sed = ρ_0 d_a² g / (18 μ_air). Deposition probability per generation scales with residence time τ_G = L_G / U_G. Total conducting airway deposition is the product of throat transmission and bronchial sedimentation: η_cond(d_a) = P_oropharynx_pass(d_a) · P_G2-G14_sed(d_a). Numerical integration across all branching generations reveals a sharp parabolic optimum centered at three micrometers, where throat impaction losses and alveolar bypass remain balanced. This coupled aerodynamic model is executed deterministically in src/scripts/delivery-weibel-deposition.js.
Interactive Governing Relation: Click or scrub the primary parameter or inspect the governing equation to perturb the coupled workbench in Act III.
Four-Stage Mechanistic Progression
- Stage 1 (Oropharyngeal Bend & Stokes Impaction — G_0): At the 90° bend of the throat, inertial impaction scales with the Stokes number St = ρ_0 d_a² Q_insp / (18 μ D³); slow, deep inhalation (~15–20 L/min) and MMAD ≈ 2.5–3.8 μm minimize throat loss.
- Stage 2 (Bronchial Bifurcations & Conducting Zone Target — G_2 to G₁₄): As the airway branches 2^G times in Weibel's symmetric tree, total cross-sectional area expands and air velocity U_G drops, allowing 2–4 μm droplets to settle onto the bronchial and bronchiolar epithelium where submucosal glands and CFTR reside.
- Stage 3 (First-Generation Clinical Lessons — MRT5005 / RESTORE-CF): Rowe et al. (J. Cyst. Fibros. 2023, PMID 37121795) showed that inhaled LNP-mRNA could be administered safely across repeat doses, while highlighting the need for higher endosomal escape potency and controlled febrile/TLR reactogenicity.
- Stage 4 (Next-Generation Clinical Pipeline): Current studies test higher-potency inhaled LNP-mRNAs (VX-522, ARCT-032, RCT2100), inhaled AAV capsids evolved for human mucus/apical entry (4D-710), and Sendai F/HN-pseudotyped lentiviruses (BI 3720931) that integrate into airway progenitors.
Act III · Interactive Visual Experiment & Plain-Language Lens
Try It Yourself: Weibel Bronchial Deposition & Modality Comparator
Adjust Mass Median Aerodynamic Diameter (median droplet size) and inspiratory flow rate (inhalation speed) to compute regional deposition across Oropharynx (G_0), Conducting Airways (G_2–G₁₄), and Alveoli (G_{17+}).
The human lung branches 23 times from the windpipe down to the air sacs. CF mucus plugging starts in the middle and small conducting airways (generations 8 to 16). If mist droplets are too large (>5 µm) or inhaled with a fast gasp, inertia slams them into the back of the throat; if they are too tiny (<0.5 µm), they float all the way to the air sacs or are breathed right back out. Adjust the droplet size and breathing flow below to steer the mist into the green conducting-airway target zone.
Questions to discuss with a CF care team: How does slow, steady tidal breathing during nebulization improve how much medicine reaches the small airways?
What this diagram leaves out: Symmetric Weibel branching models a uniform lung; in CF, mucus plugs divert airflow toward healthier segments.
Weibel Lung Tree Activity · Mode: Biophysical Sandbox · How to explore this model
- Test the four physical regimes: Click the four scenario presets below (1 · Oropharyngeal Bend &… through 4 · Next-Generation Clinical…) to jump directly between experimental conditions.
- Perturb the primary control: Drag Mass Median Aerodynamic Diameter (median droplet size) (1.0 to 7.5 μm) and observe how the visual schematic and readouts respond.
- Explore coupled co-perturbation: Adjust Inspiratory Flow Rate (inhalation speed) (10.0 to 45.0 L/min) to test synergy against
St = ρ_0 d_a² U_G / (18 μ_air D_G) · η_cond(d_a) = P_oropharynx_pass(d_a) · P_G2-G14_sed(d_a).
Governing law: St = ρ_0 d_a² U_G / (18 μ_air D_G) · η_cond(d_a) = P_oropharynx_pass(d_a) · P_G2-G14_sed(d_a)
St = ρ_0 d_a² U_G / (18 μ_air D_G) · η_cond(d_a) = P_oropharynx_pass(d_a) · P_G2-G14_sed(d_a)
Normalized Sensitivity (Stages 1–4)
Want to test this mechanism inside the full multi-module pillar observatory? Open the coupled interactive workbench on the Pillar Hub.
Act IV · Clinical & Therapeutic Horizon
Questions to Take to Your CF Care Team
Our Recruiting Trials explorer (cf/trials/) tracks active interventional clinical trials across these exact inhaled genetic modalities from a dated snapshot of ClinicalTrials.gov. Because heterogeneous mucus plugging in advanced CF can deflect airflow away from obstructed lobes ('ventilation steal'), clinical protocols increasingly pair bronchodilators and airway clearance before nebulization so the aerosol reaches the bronchioles that need it most. Grounded in Lab Discovery Catalog modules: `ali_airway_lnp_transfection_kinetics`, `aav_tropism_model`, `vector_redosing_kinetics`.
The clinical trial results reported by Rowe and colleagues provide vital translational benchmarks for inhaled genetic medicines in cystic fibrosis. The interim evaluation of MRT5005 established that repeated nebulization of messenger ribonucleic acid formulated in lipid nanoparticles is clinically feasible in adults with cystic fibrosis, causing no vector-directed neutralizing antibodies that would prevent subsequent dosing. This finding resolves a central limitation of recombinant adeno-associated viral vectors, where high circulating capsid-neutralizing titers develop after a single exposure, durably blocking repeat administration in pulmonary tissues.
However, translating these aerodynamic and immunologic insights into restorative therapies for patients carrying nonsense, frameshift, or rare non-responsive CFTR mutations requires overcoming substantial clinical hurdles. Phase I/II trial data indicated that early formulations yielded variable forced expiratory volume improvements, reflecting suboptimal endosomal escape efficiency and mild, transient febrile reactions mediated by Toll-like receptor recognition of delivered ribonucleic acids. Next-generation clinical candidates such as VX-522, ARCT-032, and Sendai virus-pseudotyped lentiviruses incorporate chemically modified nucleosides (such as N1-methylpseudouridine) to eliminate pattern-recognition receptor activation while maximizing translation. Furthermore, optimizing vibrating-mesh nebulizers to maintain narrow droplet distributions between two and four micrometers ensures reliable deposition across plugged bronchioles without excessive throat loss. Continuous clinical refinement across nebulizer engineering and synthetic biology establishes an evidence-based roadmap for long-term pulmonary gene replacement across all genetic variants. Precise aerosol targeting bridges the critical divide between laboratory formulation and clinical efficacy.
Primary Anchor: Rowe et al. (2023), Journal of Cystic Fibrosis 22(4):656-664 — Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled Phase I/II clinical evaluation (PMID 37121795). (DOI 10.1016/j.jcf.2023.04.008 · PubMed 37121795).
Governed by biophysical kernel src/scripts/delivery-weibel-deposition.js and cross-checked in the Open Weibel Bronchial Aerosol Deposition Workbench on /cf/delivery/.
Resumen Científico en Español (ES-MX) · Folio D.05
ARNm Inhalado y Vectores Virales en la Clínica: Lecciones de RESTORE-CF, VX-522, ARCT-032 y BI 3720931: Cómo la ramificación bronquial de Weibel (G_0–G₁₆), el número de Stokes de impactación de aerosoles y la inmunogenicidad guían los ensayos clínicos actuales.
Para tratar la vía aérea por inhalación, la gota de aerosol necesita un diámetro aerodinámico entre 1.5 y 4.5 micrómetros: las gotas mayores de 5 μm impactan en la orofaringe y las menores de 1 μm pasan de largo hacia los alvéolos.
En Palabras Sencillas: Para visualizar cómo viajan las gotas inhaladas, imagine lanzar pelotas de goma a través de un bosque tupido de árboles ramificados. Si lanza una pelota pesada con gran fuerza, choca de inmediato contra el primer tronco grande que encuentra en el camino. Si suelta una pluma liviana en el viento, flota más allá de las ramas sin aterrizar en los troncos medianos. Los aerosoles médicos enfrentan exactamente el mismo reto físico dentro de los pulmones humanos. Esto crea un filtro aerodinámico sumamente estricto. La garganta forma una curva pronunciada donde las gotas grandes y veloces se estrellan antes de ingresar a la tráquea. Las células blanco cubren las ramas intermedias donde las vías respiratorias se estrechan y la velocidad del aire desciende. Las gotas deben tener el tamaño exacto para esquivar la primera curva y depositarse en la superficie bronquial. Coordinar el diámetro de la gota y la velocidad de inhalación asegura que el cargamento genético alcance las zonas enfermas.
Analogía Cotidiana: Considere un tren expreso que avanza por una red ferroviaria que se bifurca rápidamente en vías cada vez más estrechas. En la entrada de la terminal, la vía principal efectúa una curva cerrada de noventa grados alrededor de una montaña rocosa. Si el convoy encara esa primera curva a gran velocidad, los vagones pesados descarrilan y se estrellan de lleno contra la pared rocosa. Por el contrario, si el tren se compone de planeadores de madera sumamente ligeros, flotan sobre las estaciones intermedias y terminan en ciénagas lejanas. Para entregar pasajeros en las estaciones intermedias deseadas, los vagones deben tener una masa moderada y viajar a velocidades controladas. Esta comparación ferroviaria pierde validez porque los trenes corren sobre rieles metálicos con frenado manual, mientras que las gotas en aerosol siguen líneas de flujo estocásticas gobernadas por arrastre viscoso y gravedad en vías respiratorias.
Guía de Controles Interactivos: Antes de revisar las fórmulas de mecánica de fluidos, los controles interactivos inferiores le permiten ajustar las variables del inhalador y la respiración. El primer control fija el Diámetro Aerodinámico Mediano de Masa, definiendo el tamaño promedio de las gotas generadas por el nebulizador. El segundo control regula la Tasa de Flujo Inspiratorio, indicando con qué rapidez inhala el paciente durante cada respiración del aerosol. Observe cómo un flujo excesivo o gotas demasiado grandes incrementan la Pérdida por Impactación Orofaringea en la parte posterior de la garganta. En paralelo, examine la lectura de Deposición en Vías Respiratorias de Conducción, que cuantifica el porcentaje que alcanza los bronquios afectados. Note que las gotas diminutas escapan hacia la Fracción Alveolar o Exhalada sin posarse en el epitelio bronquial diana. Finalmente, la Ausencia de Penalización por Anticuerpos Neutralizantes resalta la ventaja de las nanopartículas lipídicas frente a los virus convencionales.
Riesgo Biofísico y Clínico: Las implicaciones clínicas de la administración de terapias genéticas por aerosol se centran en depositar partículas terapéuticas en los bronquios de conducción evitando la impactación en la garganta y la inflamación sistémica. Rowe y colaboradores documentaron la primera evaluación aleatorizada de ácido ribonucleico mensajero inhalado administrado de forma repetida en fibrosis quística. Sus resultados confirmaron que las nanopartículas lipídicas no virales pueden nebulizarse en dosis múltiples sin inducir anticuerpos neutralizantes que bloqueen aplicaciones posteriores. Sin embargo, el ensayo reveló que la eficacia clínica exige conciliar la física de deposición aerodinámica con umbrales de escape endosomal intracelular. Las gotas deben depositarse específicamente entre las generaciones dos y catorce de Weibel, donde predomina la obstrucción mucosa en la enfermedad pulmonar. Asimismo, reacciones febriles leves observadas a dosis elevadas subrayan la estrecha ventana entre la producción funcional de canales de cloruro y la activación inmune por receptores de reconocimiento de patrones. Optimizar la aerodinámica del aerosol representa el camino crítico para formulaciones clínicas avanzadas como VX-522 y ARCT-032.
Derivación Formal: La mecánica de fluidos de la deposición de aerosoles en el tracto respiratorio se rige por leyes de impactación inercial, sedimentación gravitacional y difusión browniana a través de las veintitrés generaciones dicotómicas del modelo pulmonar de Weibel. En la vía aérea superior y faringe (generación cero), la velocidad lineal elevada del aire genera intensas fuerzas inerciales en la curva orofaríngea de noventa grados. La desviación de las gotas respecto a las líneas de corriente depende del número adimensional de Stokes, St = ρ_0 d_a² U_G / (18 μ_air D_G), donde ρ_0 es la densidad unitaria, d_a el diámetro aerodinámico, μ_air la viscosidad del aire y D_G el diámetro de la luz bronquial. Cuando el número de Stokes supera valores críticos, la inercia vence al arrastre viscoso provocando impactación en la mucosa faríngea. Al penetrar las bifurcaciones bronquiales desde la generación dos a la catorce, el área transversal total se duplica en cada nivel, reduciendo la velocidad del aire a centímetros por segundo. En esta zona de conducción, la sedimentación gravitacional pasa a ser el mecanismo preponderante, con una velocidad de caída v_sed = ρ_0 d_a² g / (18 μ_air). La probabilidad de deposición por generación escala con el tiempo de residencia τ_G = L_G / U_G. La deposición total en vías de conducción resulta del producto de transmisión faríngea y sedimentación bronquial: η_cond(d_a) = P_oropharynx_pass(d_a) · P_G2-G14_sed(d_a). Este modelo aerodinámico acoplado se ejecuta determinísticamente en src/scripts/delivery-weibel-deposition.js.
Frontera Traslacional: Los resultados de ensayos clínicos comunicados por Rowe y colaboradores proporcionan parámetros de referencia cuantitativos indispensables para la terapia génica inhalada en fibrosis quística. La evaluación del ensayo MRT5005 demostró que la nebulización repetida de ácido ribonucleico mensajero en nanopartículas lipídicas es viable en adultos con fibrosis quística sin desencadenar anticuerpos neutralizantes contra el vector. Este hallazgo resuelve una desventaja histórica de los vectores de virus adenoasociados, donde los anticuerpos impiden la readministración tras una sola dosis. No obstante, transformar estos avances en tratamientos terapéuticos para pacientes con mutaciones de terminación prematura o deleciones estructurales exige resolver retos considerables. Los datos clínicos preliminares mostraron una recuperación variable de la función pulmonar, atribuible a bajas tasas de escape endosomal y a respuestas inflamatorias transitorias mediadas por receptores tipo Toll. Formulaciones de nueva generación como VX-522 y vectores lentivirales incorporan nucleósidos químicamente modificados para silenciar la activación inmune y maximizar la traducción ribosómica. Paralelamente, la optimización de nebulizadores de malla vibrante para calibrar el diámetro de gota entre dos y cuatro micrómetros garantiza una deposición uniforme en bronquiolos obstruidos, consolidando una plataforma sólida para la medicina genética traslacional.
Horizonte terapéutico: Sintetiza la física de aerosoles en el árbol bronquial de Weibel con la inmunología de vectores (redosificación de LNP no virales frente a lentivirus pseudotipados F/HN). Investigación independiente, no asesoramiento médico.
Act V · Primary Sources, Scite Audit & Companion Tools
Primary Evidence & Verification Ledger
Each monograph names its primary literature anchor. An automated verifier checks that its DOI, PubMed ID, and citation metadata resolve against Crossref and NCBI PubMed. Workbench values are illustrative model outputs, not clinical measurements, unless a primary source is named beside them.
- Primary Literature Receipt: Rowe et al. (2023), Journal of Cystic Fibrosis 22(4):656-664 — Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled Phase I/II clinical evaluation (PMID 37121795). (DOI 10.1016/j.jcf.2023.04.008 · PubMed 37121795).
- Citation Context (Scite): Inspect how later literature cites 10.1016/j.jcf.2023.04.008 on Scite.ai ·
Crossref + Scite verified (data/folio-citations.cache.json · fetched 2026-11-08 · 173 citing · 0 supporting · 105 mentioning · 0 contrasting). - Open-Source Computational & Epistemic Engine: Scite Smart Citations & Crossref Retraction Watch Safety Gate (DOI 10.1162/qss_a_00146 · Scite Report).
- Open-Source Reproducibility: Biophysical kernels and evidence verifiers are maintained in github.com/senseiewok/cf-research and github.com/senseiewok/cf-skills.
For builders: method, companion SKILL.md, Python verifier, and edition history (REV 1.1)
cf-weibel-aerosol-clinical-vectors-SKILL.md · Kernel src/scripts/delivery-weibel-deposition.js
Load this companion skill into Claude Code, GitHub Copilot, Cursor, Antigravity, or local Ollama models (Qwen 3.8 27B, Gemma 4 31B) to enforce the governing biophysical equations and citation guardrails.
View raw SKILL.md source
--- name: cf-weibel-aerosol-clinical-vectors description: AI-agnostic aerosol physics and translational skill for Weibel bronchial deposition (G_0-G_16), Stokes impaction vs sedimentation, and inhaled CF mRNA/viral vector modalities. license: CC-BY-4.0 --- # D.05 — Inhaled mRNA & Viral Vectors in the Clinic (VX-522, ARCT-032, Lentivirus) ## Governing Biophysical / Mathematical Law St = ρ_0 d_a² U_G / (18 μ_air D_G) · η_cond(d_a) = P_oropharynx_pass(d_a) · P_G2-G14_sed(d_a) ## Primary Evidence Receipt - **Citation:** Rowe et al. (2023), Journal of Cystic Fibrosis 22(4):656-664 — Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled Phase I/II clinical evaluation (PMID 37121795). - **DOI:** https://doi.org/10.1016/j.jcf.2023.04.008 - **PubMed PMID:** https://pubmed.ncbi.nlm.nih.gov/37121795/ - **Answer Tier:** T2 · Sourced Clinical Trial & Aerosol Deposition Model ## Verification Rules - Compute upper-airway inertial impaction via the Stokes number St = rho_0 * d_a^2 * U / (18 * mu * D) and mid-bronchiolar gravitational sedimentation via v_s = rho_0 * g * d_a^2 / (18 * mu). - Target MMAD d_a ~ 2.5-3.8 um with slow inhalation (15-20 L/min) to maximize conducting-zone (G_2-G_14) deposition. - Enforce rule AH-1: include the NLM disclaimer and state that clinical trial summaries are research information, not medical advice. ## Safety & Clinical Boundary Research synthesis and biophysical modeling only — never medical advice, clinical guidance, or a treatment promise.
REV 1.1 (2026-11-04): Informatico magazine parity, Split Workbench (Plates A & B + 4-stage stepper), and live Crossref/PubMed citation gate verification.
Verified 5-Act magazine flow, untruncated headings, and bilingual EN / ES-MX structural parity.
Audited clinical dignity boundaries, non-promise guardrails, and discovery catalog coverage.
check_folio_citations.py
Verified DOI 10.1016/j.jcf.2023.04.008 against Crossref and NCBI PubMed metadata.
src/scripts/delivery-weibel-deposition.js
Coupled governing relation St = ρ_0 d_a² U_G / (18 μ_air D_G) · η_cond( to interactive Plates A & B.